**Details phase 3 trials COVID-19 vaccine candidates**

| | AstraZeneca | Moderna | Pfizer/BioNtech | Janssen | Sanofi* | CureVac* | |
|---|---|---|---|---|---|---|---|
| **Vaccine** | AZD1222<br>$5x10^{10}$ vp | mRNA-1273<br>100 ug | BNT162b2 RNA<br>30ug | Ad26.COV2.S<br>$5\times10^{10}$ vp | preS dTM<br>5 ug | cVnCoV | |
| **Platform** | Viral vector | mRNA | mRNA | Viral Vector | Protein subunit | mRNA | |
| **Control** | saline | saline | saline | saline | | | |
| **administration** | im | im | im | im | im | im | |
| **Number of participants** | Vaccine: 20.000<br>Control:10.000 | Vaccine: 15.000<br>Control 15.000 | Vaccine: 21,999<br>Control: 21,999 | Vaccine: 30.000<br>Control: 30.000 | 30-35.000 | | |
| **Age groups** | >18 yrs:<br>18-65<br>≥ 65 (at least 25% of total group) | >18 yrs:<br>≥ 65,<br><65 at risk<br><65 not at risk<br>25-40% in 2 risk groups | ≥16 years:<br>16-55 yrs<br>>55, at least 40% of total | ≥18 - <60 years<br>≥60 years min 30%.<br>(@20% 18-40 yrs) incl. with comorbidities | >18 years<br>incl. elderly and co-morbidities | | |
| **Number of vaccine doses** | 2 (D1, D29) | 2 (D1, D29) | 2 (D1, D22) | 1 | 1 | | |
| **Blood collection** | Day 1, 15, 43 | Day 1, 29, 57, 209, 394, 759 | Day 1, 8, 22, 29, 36.<br>Month 6, 12, 24 post dose2 | Day 1, 29, 71, Month 6, 12, 18, 24 | | | |
| **Follow-up** | 2 years | 2 years | 2 years | 2 years + 1 month | | | |
| **Primary objective** | - VE for prevention of COVID-19,<br>-safety and tolerability | -VE to prevent COVID-19<br>-safety and reactogenicity | VE at least 7 days after dose 2. | -VE prevention moderate, severe COVID<br>-safety | | | |
| **Primary endpoint** | SARS2 PCR<br>150 events in not seropositive participants | SARS2 PCR<br>151 events in not seropositive participants | SARS2 PCR<br>164 events in not seropositive participants | SARS2 PCR<br>154 events in not seropositive participants | | | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | baseline. For VE 60%<br>-(S)AEs | baseline. For VE 60%<br>-(S)AEs | baseline. For VE 60%<br>-(S)AEs | baseline, VE60%<br>-(S)EAs | | | |
| **Secondary objective** | -Prevention of infection<br>-VE different case definitions incl severe COVID | -VE severe COVID,<br>-VE serologically confirmed COVID<br>-immunogenicity | -immunogenicity 360 participants | -prevention infection and mild COVID-19<br>-immunogenicity | | | |
| **Secondary endpoint** | -seroconversion ab against N<br>-symptoms<br>-b-ab S<br>-Neut ab | Serum bAb levels against SARS-CoV-2 S-, N-protein by ligand-binding assay, nAb | | -binding Ab ELISA<br>-Neutr ab | | | |
| **Interim analysis efficacy** | 1, after 75 cases with VE 70-75% | 2, after 53 and 106 cases with VE >=72% | 4, first after 32 cases if VE>=77% | Set of 4 predefined criteria | | | |
| **First indication VE data available** | End Dec 2020 | End nov 2020 | End Oct 2020 | | | | |
| | | | | | | | |
| | | | | | | | |

* Phase 3 trials not started yet, protocol not finalized